NCT02963311View on ClinicalTrials.gov

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 13, 2016

Primary Completion Date

October 8, 2018

Study Completion Date

October 8, 2018

Conditions
Homozygous Familial Hypercholesterolemia
Interventions
DRUG

ALN-PCSSC

ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.

DRUG

Standard of Care

Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.

Trial Locations (3)

2193

Research Site 227001, Parktown

90001

Research Site 201001, Los Angeles

Unknown

Research Site 231001, Amsterdam

Sponsors
All Listed Sponsors
lead

The Medicines Company

INDUSTRY

NCT02963311 - A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH) | Biotech Hunter | Biotech Hunter